Skip to main content

Table 1 Characteristics of the included COS development studies in prostate cancer (n = 11)

From: A scoping review of core outcome sets and their ‘mapping’ onto real-world data using prostate cancer as a case study

First Author [ref]YearStudy typeTarget populationMethods for consensusType of participantsNumber of participantsGeographical origin
Auvinen A [21]1996COS for clinical trials or clinical researchMen aged 56–67 eligible for screeningMeetingClinical experts; non-clinical research experts26Europe, Canada, United States
Chen RC [22]2014COS patient reported outcomesAdult patients (19+) with localized and advanced cancerSystematic literature review; meetingClinical experts; non-clinical research experts; public representativesNANA
Dawson NA [23]1998COS for clinical trials or clinical researchPatients with hormone-refractory prostate cancerSurveyClinical experts35Europe, Canada, United States
Denis L [24]1997COS for clinical trials or clinical researchEspecially patients with localized cancerMeetingClinical experts; others6Europe, United States
MacLennan S [25]2017COS for clinical trials or clinical researchPatients aged 45–75 with localized prostate cancer undergoing surgery, active surveillance, ablative therapy, hormonal therapyMeeting; Delphi; focus group; systematic literature reviewClinical experts; public representatives105 patients + 47 clinical expertsEurope, United States
Martin NE [26]2015COS for practiceMen with newly diagnosed localized (stages T1-T4) cancer treated with curative intent or followed-up with active surveillanceDelphi; teleconferences; surveyClinical experts; non-clinical research experts; public representativesNANA
Middleton RG [27]1995COS for clinical trials or clinical researchPatients with stage T2(B) prostate cancer undergoing radical prostectomy, radiation therapy, or surveillanceLiterature reviewNANAUnited States
Morgans A [28]2015COS for practiceMetastatic and recurrent patients ineligible for further curative therapyDelphi; literature review; teleconferencesClinical experts; non-clinical research experts; public representatives25Europe, Australia, Canada, United States
Schellhammer P [29]1997COS for clinical trials or clinical researchPatients with localized cancerLiterature review; conferenceClinical experts; othersNAEurope, Canada, United States
van den Bos W [30]2014COS for clinical trials or clinical researchPatients with localized cancer and candidates for focal therapyDelphi; meeting; literature reviewClinical experts48North America, Europe and Asia
van den Bos W [31]2015COS for clinical trials or clinical researchPatients with localized recurrent disease after radiation therapyDelphi; meeting; literature reviewClinical experts55NA
  1. COS Core outcome set, NA Not available